-
Dextrose (D-Glucose) as a Metabolic Control Variable
2026-09-12
Dextrose (D-glucose) is more than a routine nutrient: it is a controllable variable for resolving nutrient competition, hypoxia, and cellular energy production. This guide connects product quality and handling with assay architecture for glucose metabolism research, tumor immunometabolism, and related cell studies.
-
Tuning Stem Cell Fate with CHIR 99021
2026-09-11
CHIR 99021 trihydrochloride is more than a potent GSK-3 inhibitor: it is a controllable experimental input for connecting stemness, differentiation, organoid scalability, and metabolic research. This thought-leadership article interprets the tunable human intestinal organoid study through a translational lens, while defining practical validation strategies, limitations, and opportunities for CHIR-based experimental design.
-
Toremifene in Prostate Cancer Research
2026-09-11
Toremifene is a second-generation selective estrogen-receptor modulator used to study estrogen receptor signaling and hormone-responsive cancer biology. Product data report an in vitro cell growth inhibition benchmark of approximately 1 ± 0.3 μM in Ac-1 cells, while prostate cancer metastasis research identifies the TSPAN18–STIM1–TRIM32 axis as a separate calcium-signaling framework for mechanistic comparison.
-
VX-702 and the Next Era of p38α MAPK Research
2026-09-10
VX-702 offers translational researchers a selective, ATP-competitive route to interrogate p38α MAPK signaling, connect cytokine biology with tissue outcomes, and test how kinase conformation may shape phosphatase-mediated pathway shutdown.
-
ddATP Workflows for DNA Synthesis Termination
2026-09-10
Learn how ddATP converts nucleotide incorporation into a controllable endpoint for Sanger sequencing, PCR termination assays, enzyme studies, and DNA-repair research. This workflow-focused guide translates evidence from mouse-oocyte ssBIR research into practical controls, dose-finding strategies, and troubleshooting decisions.
-
ATS-9R/siCcl2 Targeting of ATMs in GDM
2026-09-09
The reference study developed an ATS-9R/siCcl2 complex to suppress CCL2 in adipose tissue macrophages and investigated its effects on inflammation and insulin resistance in gestational diabetes mellitus. Its main contribution is a cell- and tissue-directed, non-viral gene-silencing strategy that links ATM inflammation with calcium dysregulation, mitochondrial oxidative stress, and metabolic impairment.
-
C34 TLR4 Inhibitor: Assay Workflow Guide
2026-09-09
C34 enables selective interrogation of TLR4-driven inflammation in macrophage, enterocyte, and microglial models without treating broad inflammatory suppression as target validation. This workflow guide translates reference-study findings into practical dosing, controls, troubleshooting, and translational assay choices.
-
ATG9A, PTOV1, and 14-3-3 Cancer Mechanisms
2026-09-08
The reference study identifies ATG9A and PTOV1 as previously unrecognized 14-3-3-interacting proteins and defines distinct mechanisms linking them to basal autophagy and oncogenic signaling. Its combination of proximity labeling, quantitative proteomics, and biochemical validation provides a useful framework for interpreting regulated protein stability, trafficking, and degradation in cancer biology.
-
Meropenem Trihydrate for Resistance Research
2026-09-08
Meropenem trihydrate is a broad-spectrum carbapenem antibiotic used to investigate bacterial cell wall inhibition, antimicrobial activity, and resistance phenotypes. The 2025 reference study shows that LC-MS/MS metabolomics distinguished carbapenemase-producing Enterobacterales from non-producing isolates in under 7 hours, but the assay was a resistance-detection workflow rather than a meropenem susceptibility test.
-
AL-8810: A Causal Map of FP Signaling
2026-09-07
AL-8810 is a prostaglandin F2α antagonist suited to receptor-level analysis of PGF2α responses. This article develops a causal assay framework linking FP receptor pharmacology with ERK1/2, MMP-2, vascular, and endometrial readouts while distinguishing established evidence from experimental strategy.
-
Full-Length αvβ3 Integrin: Cryo-EM Structural Diversity
2026-09-07
The reference study uses high-resolution cryo-EM to map full-length human αvβ3 integrin across six apo conformations and five ligand-bound states, including five previously uncharacterized intermediates. Its continuum model clarifies how inhibitors engage distinct receptor states and provides a structural basis for more selective integrin drug design.
-
TSPAN18–STIM1 Signaling in Prostate Cancer Bone Metastasis
2026-09-05
Zhou et al. identify TSPAN18 as a stabilizing regulator of STIM1, showing that it protects STIM1 from TRIM32-mediated ubiquitination and degradation. The resulting STIM1-dependent calcium influx promotes prostate cancer cell migration, invasion, and bone metastasis, providing a mechanistic framework for studying calcium signaling in metastatic disease.
-
Clarithromycin in Viability Assays
2026-09-04
Learn how Clarithromycin (SKU A4322) can clarify CYP3A-mediated confounding in cell viability, proliferation, cytotoxicity, and drug-drug interaction experiments. This scenario-based guide covers solvent handling, controls, interpretation, protocol design, and practical product-selection criteria.
-
Phytol RXR Assay Workflow and Optimization
2026-09-04
Build more interpretable RXR experiments with a controlled Phytol workflow that separates receptor signaling from solvent, isomer, and metabolic confounders. A polymer self-assembly study adds a practical design principle: systematically vary composition and matrix conditions rather than assuming one formulation will fit every assay.
-
OSMI-1 for O-GlcNAc Transferase Inhibition
2026-09-03
OSMI-1 provides a cell-permeable loss-of-function approach for connecting OGT activity with HUWE1, TfR1, iron handling, ferroptosis, and trophoblast syncytialization. This guide translates the latest preeclampsia findings into practical dose-finding, target-engagement, phenotype, and troubleshooting workflows.